Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOX) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 13,800 shares, a decline of 81.1% from the September 30th total of 73,000 shares. Based on an average daily volume of 626,600 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Bionomics in a research report on Thursday, August 1st.

Bionomics Trading Down 31.5 %

Shares of BNOX stock traded down $0.11 during mid-day trading on Friday, reaching $0.25. 4,017,426 shares of the company’s stock traded hands, compared to its average volume of 541,273. Bionomics has a 12 month low of $0.23 and a 12 month high of $3.03. The firm has a 50 day moving average price of $0.50 and a two-hundred day moving average price of $0.71.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new stake in shares of Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.